Form 4: Unity Biotechnology CEO Anirvan Ghosh Reports Acquisition of Shares and Stock Options
SEC Form 4
Anirvan Ghosh, CEO of Unity Biotechnology, reports the acquisition of restricted stock units and stock options following the satisfaction of performance criteria.
Summary
- Anirvan Ghosh, the CEO of Unity Biotechnology, filed a Form 4 detailing changes in beneficial ownership.
- On March 28, 2025, Ghosh acquired 175,000 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- These RSUs were granted on January 30, 2024, and vested upon meeting specific performance criteria.
- Ghosh also acquired an option to purchase 286,000 shares of common stock, granted on January 30, 2024.
- Half of these option shares vested on March 28, 2025, upon meeting performance criteria, with the remaining shares vesting in 12 equal monthly installments.
- Following these transactions, Ghosh directly owns 250,251 shares of common stock and holds options for 286,000 shares.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the vesting of RSUs and stock options suggests the achievement of performance goals. The CEO's increased stake in the company can be viewed favorably.
Positives
- The vesting of RSUs and stock options indicates that performance criteria were met, suggesting positive progress within the company.
Future Outlook
The remaining half of the stock options will vest in 12 successive, equal monthly installments, subject to the Reporting Person's continued service to the Issuer.
Industry Context
Form 4 filings are standard practice for company insiders and provide transparency regarding their transactions in the company's securities. This filing indicates the CEO's continued investment and stake in Unity Biotechnology.
Stakeholder Impact
- Shareholders may view the vesting of RSUs and stock options positively, as it indicates the CEO's commitment and the achievement of performance targets.
- Employees may be motivated by the company's progress and the CEO's increased stake.
Next Steps
- The remaining half of the stock options will continue to vest in monthly installments.
Key Dates
| Date | Description |
|---|---|
| January 30, 2024 | Board of Directors granted the Reporting Person 175,000 Restricted Stock Units (RSUs) and an option to purchase 286,000 shares of common stock. |
| March 28, 2025 | Performance criteria met, resulting in vesting of 175,000 RSUs and half of the stock options (143,000 shares). |
| March 27, 2035 | Expiration date of the stock options. |
| March 31, 2025 | Date of Form 4 signature. |
Keywords
Form 4, beneficial ownership, Unity Biotechnology, Anirvan Ghosh, stock options, RSUs, UBX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.